Therapy Areas: AIDS & HIV
Gilead Phase 3 Study Results Evaluating Adult HIV Patients Who Switched to Biktarvy Regimen Presented at CROI Meeting
7 March 2018 - - Foster City, California-based global research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has released detailed 48-week results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir, and lamivudine (600/50/300mg) (ABC/DTG/3TC) to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), a once-daily single tablet regimen, in virologically suppressed adults with HIV, the company said.
Through week 48, Biktarvy was found to be statistically non-inferior to ABC/DTG/3TC with a numerically lower incidence of mild or moderate study drug-related adverse events and no treatment-emergent resistance.
The data were presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA